PULSE BIOSCIENCES, INC. Financials Pulse Biosciences, Inc.
Equities
PLSE
US74587B1017
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.19 USD | +7.47% |
|
0.00% | -41.26% |
| Apr. 01 | Sector Update: Health Care Stocks Slide Late Afternoon | MT |
| Apr. 01 | Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans | MT |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 385.7 | 235.8 | 278.8 | 604.6 | 438.8 | 103.1 |
| Enterprise Value (EV) 1 | 347.6 | 176.3 | 260.1 | 595.5 | 421.5 | 117.9 |
| P/E ratio | -13.6 x | -5.21 x | -5.92 x | -11.1 x | -6.51 x | -1.61 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 309,477,645 x | 147,317,306 x |
| EV / Revenue | - | - | - | - | 297,232,229 x | 168,485,877 x |
| EV / EBITDA | -14 x | -4.81 x | -5.56 x | -12.2 x | -6.81 x | -2.08 x |
| EV / FCF | -60.9 x | -17.9 x | -15.3 x | -31.7 x | -13.9 x | -4.39 x |
| FCF Yield | -1.64% | -5.58% | -6.54% | -3.15% | -7.21% | -22.8% |
| Price to Book | 8.63 x | 3.56 x | 9.09 x | 26.6 x | 12.3 x | -45.9 x |
| Nbr of stocks (in thousands) | 16,341 | 20,579 | 20,788 | 25,342 | 29,631 | 37,228 |
| Reference price 2 | 23.60 | 11.46 | 13.41 | 23.86 | 14.81 | 2.770 |
| Announcement Date | 3/16/18 | 3/14/19 | 3/16/20 | 3/12/21 | 3/31/22 | 3/31/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | 1.418 | 0.7 |
| EBITDA 1 | -24.81 | -36.65 | -46.79 | -48.87 | -61.87 | -56.7 |
| EBIT 1 | -25.81 | -37.96 | -47.95 | -49.96 | -63.01 | -58.06 |
| Operating Margin | - | - | - | - | -4,443.86% | -8,293.86% |
| Earnings before Tax (EBT) 1 | -25.57 | -37.54 | -46.97 | -49.85 | -63.66 | -58.5 |
| Net income 1 | -25.57 | -37.54 | -46.97 | -49.85 | -63.66 | -58.5 |
| Net margin | - | - | - | - | -4,489.42% | -8,357.86% |
| EPS 2 | -1.733 | -2.198 | -2.264 | -2.144 | -2.276 | -1.724 |
| Free Cash Flow 1 | -5.705 | -9.827 | -17.01 | -18.77 | -30.4 | -26.84 |
| FCF margin | - | - | - | - | -2,143.67% | -3,833.73% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/16/18 | 3/14/19 | 3/16/20 | 3/12/21 | 3/31/22 | 3/31/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.574 | 0.844 | 0.444 | 0.265 | - | -0.009 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -14.81 | -14.27 | -15.41 | -17.27 | -14.01 | -18.02 | -8.745 | -9.562 | -10.23 |
| Operating Margin | - | -2,486.59% | -1,825.83% | -3,890.32% | -5,288.3% | - | 97,166.67% | - | - |
| Earnings before Tax (EBT) 1 | -15.32 | -14.28 | -15.42 | -17.27 | -14 | -18.04 | -9.197 | -9.801 | -9.91 |
| Net income 1 | -15.32 | -14.28 | -15.42 | -17.27 | -14 | -18.04 | -9.197 | -9.801 | -9.91 |
| Net margin | - | -2,488.15% | -1,826.54% | -3,890.32% | -5,281.51% | - | 102,188.89% | - | - |
| EPS 2 | -0.5800 | -0.4800 | -0.5200 | -0.5800 | -0.4400 | -0.4900 | -0.2500 | -0.2600 | -0.2200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/9/21 | 11/15/21 | 3/31/22 | 5/11/22 | 8/10/22 | 11/10/22 | 3/30/23 | 5/11/23 | 8/10/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 14.8 |
| Net Cash position 1 | 38.1 | 59.6 | 18.7 | 9.12 | 17.4 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.2613 x |
| Free Cash Flow 1 | -5.7 | -9.83 | -17 | -18.8 | -30.4 | -26.8 |
| ROE (net income / shareholders' equity) | -71.7% | -66.8% | -96.8% | -186% | -217% | -350% |
| ROA (Net income/ Total Assets) | -42.4% | -39.4% | -53.3% | -75.1% | -82.4% | -54.9% |
| Assets 1 | 60.33 | 95.31 | 88.2 | 66.41 | 77.22 | 106.5 |
| Book Value Per Share 2 | 2.730 | 3.220 | 1.480 | 0.9000 | 1.200 | -0.0600 |
| Cash Flow per Share 2 | 0.2000 | 2.480 | 0.3300 | 0.4900 | 0.9600 | 1.640 |
| Capex 1 | 2.55 | 0.28 | 0.61 | 0.44 | 0.44 | 0.4 |
| Capex / Sales | - | - | - | - | 30.82% | 57.29% |
| Announcement Date | 3/16/18 | 3/14/19 | 3/16/20 | 3/12/21 | 3/31/22 | 3/31/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -41.26% | 397M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| +26.76% | 32.03B |
- Stock Market
- Equities
- PLSE Stock
- Financials Pulse Biosciences, Inc.
